Real-world long-term outcomes of non-small cell lung cancer patients undergoing neoadjuvant treatment with or without immune checkpoint inhibitors
Bolun Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Shugeng Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Fengwei Tan(Chinese Academy of Medical Sciences & Peking Union Medical College), Liang Zhao(Paraza Pharma (Canada)), Wei Guo(Chinese Academy of Medical Sciences & Peking Union Medical College), Fan Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Lin Li(China Pharmaceutical University), Qi Xue(Chinese Academy of Medical Sciences & Peking Union Medical College), Qilin Huai(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 3
Related Papers
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
|Journal of Thoracic Oncology|2020|415
Mouse Embryonic Head as a Site for Hematopoietic Stem Cell Development
|Cell stem cell|2012|192
A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer
|Cell|2025|103